BioSpace News Archive

MAIA Biotechnology, Inc. announced that independent director Stan V. Smith, Ph.D. made an individual purchase of 147,492 shares, and warrants for 147,492 shares, of MAIA’s common stock as part of the Company’s recent private placement of common stock and warrants.

Microbot Medical Inc., developer of the innovative LIBERTY® Endovascular Robotic Surgical System, reports that the first phase of the previously announced collaboration with Corewell Health has been completed, which demonstrated the LIBERTY® System’s technical capabilities and outlines potential future applications in a range of endovascular interventions.

Hypha Labs, Inc. (OTC Pink:DIGP) has announced that it has made Craig Ellins its Chief Science Officer. Hypha Labs, Inc. changed its name from Digipath, Inc. after the sale of its cannabis lab assets.

AIM ImmunoTech Inc. announced that it has taken an essential step forward in testing the combination of AIM’s Ampligen® and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® in the treatment of late-stage pancreatic cancer.

SELLAS Life Sciences Group, Inc. today announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC).

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) is partnering with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced it will present at the OIS Retina Innovation Showcase being held May 4, 2024 in Seattle, WA.

Lexicon Pharmaceuticals, Inc. announced that Lonnel Coats has provided notice of his retirement as chief executive officer and as a member of its board of directors, in each case effective July 7, 2024, his 10th anniversary with the company.

Sermonix Pharmaceuticals Inc. announced that an article on the effects of its lead investigational drug, oral lasofoxifene, on moderate to severe vaginal atrophy in postmenopausal women was published April 23, 2024 in Menopause: The Journal of The Menopause Society.

Mitsubishi Tanabe Pharma America, Inc. is celebrating its eight-year anniversary of being established in the United States.